Table 1: Summary of the indications for continuous glucose monitoring in the 2015 NICE guidelines.

Adult guideline (aged ≥18 years and over)	Paediatric guideline (aged <18 years)
Consider real-time continuous glucose monitoring for adults with type 1 diabetes who are willing to commit to using it at least 70% of the time and to calibrate it as needed
More than one episode a year of severe hypoglycaemia with no obviously preventable precipitating cause	Offer ongoing real-time continuous glucose monitoring with alarms to children and young people with type 1 diabetes who have frequent severe hypoglycaemia
Complete loss of awareness of hypoglycaemia	Offer ongoing real-time continuous glucose monitoring with alarms to children and young people with type 1 diabetes who have impaired awareness of hypoglycaemia associated with adverse consequences (for example, seizures or anxiety)
Frequent (more than two episodes a week) asymptomatic hypoglycaemia that is causing problems with daily activities	Offer ongoing real-time continuous glucose monitoring with alarms to children and young people with type 1 diabetes who have inability to recognise, or communicate about, symptoms of hypoglycaemia (for example, because of cognitive or neurological disabilities)
Extreme fear of hypoglycaemia	Consider ongoing real-time continuous glucose monitoring for neonates, infants and pre-school children
Hyperglycaemia (HbA1c level of 75 mmol/mol [9%] or higher) that persists despite testing at least 10 times a day. Continue real-time continuous glucose monitoring only if HbA1c can be sustained at or below 53 mmol/mol (7%) and/or there has been a fall in HbA1c of 27 mmol/mol (2.5%) or more	Consider ongoing real-time continuous glucose monitoring for children and young people who undertake high levels of physical activity (for example, sport at a regional, national or international level)
For adults with type 1 diabetes who are having real-time continuous glucose monitoring, use the principles of flexible insulin therapy with either a multiple daily injection insulin regimen or continuous subcutaneous insulin infusion (CSII or insulin pump) therapy	Consider ongoing real-time continuous glucose monitoring for children and young people who have comorbidities (for example anorexia nervosa) or who are receiving treatments (for example corticosteroids) that can make blood glucose control difficult
Real-time continuous glucose monitoring should be provided by a centre with expertise in its use, as part of strategies to optimise a person’s HbA1c levels and reduce the frequency of hypoglycaemic episodes	Consider intermittent (real-time or retrospective) continuous glucose monitoring to help improve blood glucose control in children and young people who continue to have hyperglycaemia despite insulin adjustment and additional support

CSII = continuous subcutaneous insulin infusion; HbA1c = glycated haemoglobin; NICE = The National Institute for Health and Care Excellence.